Skip to content

News: General News

Keros Therapeutics, a company dedicated to the discovery and development of novel therapeutics for neuromuscular diseases, announced a $23 million Series B financing today. This investment, coupled with Series A in 2016, brings the company’s total venture funding to $34 million to date. The financing round included participation from existing investors Pontifax, Arkin Bio VenturesPartners Innovation Fund, and Medison Pharma, and added Global Health Sciences Fund (GHS) as a new investor.

Get the full story here